Klin Farmakol Farm. 2015;29(3):129-132

Peritoneal dialysis

Vladimíra Bednářová
Klinika nefrologie Všeobecné fakultní nemocnice a 1. LF UK Praha

Peritoneal dialysis is one of the treatment options for chronic kidney failure. It is the first-choice method of treatment in patients indicated

for deceased-donor kidney transplantation. The principle of this method consists in removing substances and water through

the peritoneum into the dialysis fluid filled into the abdominal cavity. Peritoneal dialysis is self-administered by the patient at home

and there are monthly follow-up visits at the dialysis centre. The dialysis fluid is introduced and removed from the abdominal cavity

manually (the CAPD method) or by using a device (the APD method). A peritoneal catheter is placed permanently in the abdominal

cavity. Peritonitis and fluid retention are the most serious complications. Peritonitis is treated with antibiotics administered intraperitoneally

according to sensitivity. Fluid retention is treated by adjusting the dialysis schedule (the number of exchanges) or by using

solutions with a higher glucose concentration and increasing diuretics. Peritoneal dialysis is suitable for most patients with kidney

failure. It is contraindicated in patients with peritoneal adhesions, those with hernias, or those with poor hygiene habits. The method

provides a better quality of life, the possibility of being independent of the dialysis centre, and freedom to travel, but also requires

the patient’s active approach.

catheter, icodextrine.

Keywords: peritoneal dialysis, chronic renal failure, automated peritoneal dialysis, peritonitis, dialysis fluid, implantation of the peritoneal

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bednářová V. Peritoneal dialysis. Klin Farmakol Farm. 2015;29(3):129-132.
Download citation

References

  1. Oreopoulos DG. Knowhistory of CAPD accurately. Perit Dial Int. 2009; 29(6): 678. Go to original source... Go to PubMed...
  2. Bednářová V, Dusilová Sulková S, a kol. Peritoneální dialýza. Maxdorf 2007, Praha.
  3. Rychlík I, Lopot F. Statistická ročenka dialyzační léčby v České republice v roce 2013.
  4. Blake PG, Davies SJ. PD in the UK: the past, present, and future. Perit Dial Int. 2011; 31(Suppl 2): S34-S35. Go to original source... Go to PubMed...
  5. Rippe B. Free water transport, smallpore transport and the osmotic presure gradient. Nephrol Dial Transplant 2008; 23: 2147-2153. Go to original source... Go to PubMed...
  6. Van Biesen W, Heimburger O, Krediet RT, et al. ERBP working group on peritoneal dialysis: Evalution of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. Nephrol Dial Transplant 2010; 25: 2052-2062. Go to original source... Go to PubMed...
  7. Van Biesen W, Williams JD, Covic AC, et al. Fluid status in peritoneal patients: The European body composition monitoring (Euro BCM) study cohort. PLoS ONE 2011; 6: e17148. Go to original source... Go to PubMed...
  8. Tranaeus A, for the Bicarbonate/Lactate Study Group. Along-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. Perit Dial Int 2000; 20: 516-523. Go to original source... Go to PubMed...
  9. Williams JD, Topley N, Craig KJ, et al. Euro Balance Trial Group. The Euro-Balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int2004; 66: 408-448. Go to original source... Go to PubMed...
  10. Chung SH, Stenvinkel P, Bergstrom J, et al. Biokompatibility of new peritoneal dialysis solutions: what can we hope to achive? Perit Dial Int 2000; 20: S57-S67. Go to original source... Go to PubMed...
  11. Lee HY, Park HC, Seo BJ, et al. Superior patient survival fo rcontinuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int. 2005; 25(3): 248-255. Go to original source... Go to PubMed...
  12. Boujelbane L, Fu N, Chapla K, et al. Percutaneous versus surgicalinsertion of PD catheters in dialysis patients: a meta-analysis. J Vasc Access 2015; 29. Go to original source... Go to PubMed...
  13. Figueiredo A, Goh B, Jenkins S. Clinical Practice Guidelines for Peritoneal Acces. Perit Dial Int 2010; 30: 424-429. Go to original source... Go to PubMed...
  14. Nodaira Y. Ikeda N, Kobayaski L, Watanabe Y, et al. Risk factor and cause of removal of peritoneal dailysis catheter in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2008; 24: 65-68. Go to PubMed...
  15. Riella MC, Chula DC. Peritoneal dialysis access: What's the best approach? Peritoneal dialysis state of the art 2012. Contrib Nephrol. Basel, Karger 2012: 30-34. Go to original source... Go to PubMed...
  16. La Milia V, DiFilipo S, Crepaldi M, et al. Mini-peritoneal equilibration test a simple and fast method to assess free water and small solute transport across the peritoneal membrane. Kidney Int. 2005; 68: 840-846. Go to original source... Go to PubMed...
  17. Fang W, Ni Z, Qian J. Key factors for a high-quality peritoneal dialysis program - the role of the PD team and continuous quality improvement. Perit DialInt. 2014; 34 2: S35-S42. Go to original source... Go to PubMed...
  18. Chanouzas D, Ng KP, Fallouh B, Baharani J. What influences patient choice of treatment modality at the pre-dialysis stage? Nephrol Dial Transplant. 2012; 27(4): 1542-1547. Go to original source... Go to PubMed...
  19. Courivaud C, RoubiouC, Delabrousee E, et al. Polycystic kidney size and outcomes on peritoneal dialysis: comparison with haemodialysis. Clin Kidney J. 2004; 2: 138-143. Go to original source...
  20. Li PK, Szeto CC, Piraino B, et al. ISPD. Peritoneal dialysis - related infections recommendations: 2010 update. Perit Dial Int 2010; 30: 393-423. Go to original source... Go to PubMed...
  21. Wiggins KJ, Johnson DW, Craig J, et al. Treatment of peritoneal dialysis-assotiated peritonitis: asystemic review of randomized controlled trials. Am J Kidney Dis 2004; 50: 967-988. Go to original source... Go to PubMed...
  22. Ballinger AE, Palmer SC, Wigins KJ, et al. Treatment for peritoneal dialysis - associatad peritonitis. Cochrane Database SystRev 2014. Go to original source...
  23. De Vin F, Rutherford P, Faict D. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatbility and guidance for clinical use. Perit Dial Int 2009; 29: 5-15. Go to original source... Go to PubMed...
  24. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: The London, UK, peritonitis audit 2002-2003. Perit Dial Int 2009; 29: 297-302. Go to original source... Go to PubMed...
  25. Barretti P, Pereira Doles JV, Pinotti DG, et al. Evidence-based medicine: An update on treatments for peritoneal dialysis - related peritonitis. Perit Dial Int 2015; 4: 287-294. Go to original source... Go to PubMed...
  26. Campbell DJ, Johnson DW, Mudge DW, et al. Prevention of peritoneal dialysis-related infections. Nephrol Dial Transplant 2015; 30: 1461-1472. Go to original source... Go to PubMed...
  27. Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risk of peritoneal dialysis - related infections. Perit Dial Int 2011; 31: 614-630. Go to original source... Go to PubMed...
  28. Balda S, Power A, Papalois V, Brown E. Impact of hernias on peritoneal dialysis technique survival and residual renal function. Perit Dial Int. 2013; 33(6): 629-634. Go to original source... Go to PubMed...
  29. Lam MF, Lo WK, Tse KC, Yip TP, Lui SL, Chan TM, Lai KN. Retroperitoneal leak age as a cause of acute ultrafiltration failure: its associated risk factors in peritoneal dialysis. Perit DialInt. 2009; 29(5): 542-547. Go to original source...
  30. Bednářová V, Paříková A. Stanovení propustnosti peritonea - klinické doporučení pracovní skupiny ERBP. Aktuality v nefrologii 2011; 2: 57-63.
  31. Wuerth DB, Finkelstein SH, Schwetz O, Carey H, Kliger AS, Finkelstein FO. Patients' descriptions of specific factors leading to modality selection of chronic peritoneal dialysis or hemodialysis. Perit Dial Int. 2002; 22(2): 184-190. Go to original source... Go to PubMed...
  32. Makkar V, Kumar M, Mahjan R, et al. Comparison of Outcomes and Quality of Life between hemodialysis and Peritoneal Dialysis Patients in Indian ESRD Population. J Clin Diag Res 2015; 9: 28-31. Go to original source... Go to PubMed...
  33. Van de Luijtgaarden MW, Jage KJ, Segelmark M, et al. TD. Trends in dialysis modality choice and related patien tsurvival in the ERA-EDTA Registry over a 20-year period. Nephrol Dial Transplant. 2015 gfv295. [Epubaheadofprint]. Go to original source... Go to PubMed...
  34. Pulliam J, Li NC, Maddux F, Hakim RF, et al. First-year outcomes of incident peritoneal dialysis patients in the United States. Am Kidney Dis 2014; 64(5): 761-769. Go to original source... Go to PubMed...
  35. Li PK, Chow KM. Peritoneal dialysis - first policy made successful: perspectives and actions. Am J Kidney Dis. 2013 62: 993-1005. Go to original source... Go to PubMed...
  36. Mehrotra R. Comparing outcomes of hemodialysis and peritoneal dialysis patients: consider the pitfalls. In Ronco C, Rosner MH, Crepaldi C. Peritoneal dialysis state of the art 2012. Karger 2012: 30-34. Go to original source...
  37. Burkart J.The future of peritoneal dialysis in the United States: optimizingits use. Clin J Am Soc Nephrol. 2009; 4(Suppl 1): S125-S131. Go to original source... Go to PubMed...
  38. Blake PG. Integrated end-stage renal diesase care: the role of peritoneal dialysis. Nephrol Dial Transplant. 2001; 16: 61-66. Go to original source... Go to PubMed...
  39. Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and accessissues. Adv Chronic Kidney Dis. 2011; 18: 428-432. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.